Peptides DB
Research-centric peptide and protocol reference hub
Study 43 of 43Erythropoietin (EPO) literatureRenal failure · Observational2026

Longitudinal trajectory characteristics of the erythropoietin resistance index and their association with all-cause mortality in maintenance hemodialysis patients.

The erythropoietin resistance index does not independently predict mortality in maintenance hemodialysis patients, with stronger predictors identified as dialysis vintage, sex, and hemoglobin levels.

Read at Renal failureAdd to compare

Where it sits

this study against the rest of the erythropoietin (epo) corpus
6
Preclinical
28
Observational · this one
1
Open-label
2
Randomised
6
Reviews

Summary and findings

This study evaluated the erythropoietin resistance index (ERI) in maintenance hemodialysis patients to determine its association with all-cause mortality. A total of 150 patients were reviewed, with 110 having sufficient data for analysis, and 26 patients died (23.6%). The study found that ERI did not independently predict mortality.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
23.6% mortality rate among patients with sufficient ERI data.n=1502026

Abstract

The authors’ words, as Renal failure supplied them

<h4>Objective</h4>Anemia is common in kidney failure, and most patients depend on erythropoiesis-stimulating agents (ESAs). We grouped maintenance hemodialysis (MHD) patients by how their erythropoietin resistance index (ERI) changed over time, and asked whether these patterns predicted death.<h4>Methods</h4>We reviewed records of MHD patients treated at our center between 2021 and 2025. K-means clustering was applied to repeated ERI measurements to define trajectories. Logistic regression tested whether trajectory group, continuous ERI, and ERI quartile were related to all-cause mortality, the primary outcome. We also used spline models, subgroup and sensitivity analyses, and examined whether ERI improved prediction.<h4>Results</h4>A total of 150 patients were included, and 110 had enough repeated ERI data for trajectory analysis; 26 of them died (23.6%). Baseline ERI quartiles differed in dialysis vintage, dry weight, hemoglobin, and sex. In adjusted models, none of the ERI measures-continuous, quartile, or trajectory-predicted mortality. Dialysis vintage, sex, and hemoglobin were stronger predictors, and adding ERI barely changed discrimination.<h4>Conclusions</h4>ERI varied widely between patients and tracked the severity of anemia and overall clinical state. It did not, however, show an independent association with death that we could detect. With a retrospective design and limited precision, our results are inconclusive about prognostic value rather than evidence that none exists.

Background

This paper addresses the relationship between erythropoietin resistance index (ERI) and mortality in maintenance hemodialysis (MHD) patients, a population commonly affected by anemia. Prior research has suggested that ERI may correlate with clinical outcomes, but its predictive value for mortality remains unclear. Understanding this relationship is crucial for improving patient management and outcomes in MHD.

Methods

The study employed a retrospective design, reviewing records of MHD patients treated at a single center from 2021 to 2025. A total of 150 patients were included, with 110 providing adequate repeated ERI measurements for trajectory analysis. Logistic regression was used to assess the relationship between ERI measures and all-cause mortality, the primary outcome.

Results

The primary finding indicated that none of the ERI measures—continuous, quartile, or trajectory—predicted mortality in the adjusted models. The study reported that dialysis vintage, sex, and hemoglobin were stronger predictors of mortality. The analysis included 110 patients, with 26 deaths observed (23.6%).

Interpretation

These findings suggest that while ERI varies among patients and reflects anemia severity, it does not independently predict mortality in MHD patients. This contrasts with prior studies that may have suggested a stronger link. The limitations of a retrospective design and potential confounding factors, such as small sample size and single-center data, may affect the reliability of these results.

Key findings

  • 150 patients included in the study.
  • 110 patients had sufficient repeated ERI data for trajectory analysis.
  • 26 patients died, representing 23.6% of the cohort.
  • In adjusted models, none of the ERI measures predicted mortality.
  • Dialysis vintage, sex, and hemoglobin were identified as stronger predictors.

Limitations

  • Retrospective design limits causal inference.
  • Single-center study may affect generalizability.
  • Small sample size for trajectory analysis (n=110).
  • No independent association with mortality detected.

Elsewhere in the Erythropoietin (EPO) corpus

DGlycopeptide-based classification of erythropoietin biopharmaceuticals by microseparation techniques coupled to mass spectrometry and multivariate analysis.Talanta · 2026 · Not reported in abstract.reviewDErythropoietin beyond red blood cells: Systemic and oncological functions (Review).Molecular medicine reports · 2026reviewDSodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.JAMA · 2026 · Hemoglobin changed by 0.55 g/dL in the SGLT2 inhibitor group, P<0.001.reviewBResponsiveness to Erythropoiesis‑Stimulating Agents and Hemoglobin Variability in Japanese Patients With End‑Stage Kidney Diseasebiorxiv-preprint · 2026 · ERI was positively correlated with Hb-RSD (r = 0.473, p = 0.003).HumanBBlood Free Carnitine Level is an Independent Determinant of Erythrocyte Membrane Homogeneity and Osmotic Resistance in Maintenance Hemodialysis Patientsbiorxiv-preprint · 2026 · Higher FC levels were associated with increased OFT slope a (β=0.6090, P=0.036).HumanBGenetic mimicry of haematopoietic growth factor signalling: efficacy–safety trade-offs for cytopenias by drug-target Mendelian randomisationbiorxiv-preprint · 2026 · OR 0.65, 95% CI 0.49–0.86, P=0.0026 for lower thrombocytopenia risk with higher MPL expression.Human